Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab.
about
Report from IPITA-TTS Opinion Leaders Meeting on the Future of β-Cell ReplacementUpdate on CD40 and CD154 blockade in transplant modelsAutoimmune therapies targeting costimulation and emerging trends in multivalent therapeuticsBiologics in organ transplantationIL-2-Mediated In Vivo Expansion of Regulatory T Cells Combined with CD154-CD40 Co-Stimulation Blockade but Not CTLA-4 Ig Prolongs Allograft Survival in Naive and Sensitized MiceSafety and tolerability of the T-cell depletion protocol coupled with anakinra and etanercept for clinical islet cell transplantation.Immunosuppressive Medications.Islet cell transplant and the incorporation of Tregs.Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockadeLFA-1 blockade induces effector and regulatory T-cell enrichment in lymph nodes and synergizes with CTLA-4Ig to inhibit effector function.Heterogeneity within T Cell Memory: Implications for Transplant ToleranceUpdate on islet transplantation.The Spleen Is an Ideal Site for Inducing Transplanted Islet Graft Expansion in Mice.Integrin antagonists prevent costimulatory blockade-resistant transplant rejection by CD8(+) memory T cells.Treatment with Tacrolimus and Sirolimus Reveals No Additional Adverse Effects on Human Islets In Vitro Compared to Each Drug Alone but They Are Reduced by Adding Glucocorticoids.Assessment of tissue-engineered islet graft viability by fluorine magnetic resonance spectroscopy.Transient combination therapy targeting the immune synapse abrogates T cell responses and prolongs allograft survival in mice.Islet transplantation in type 1 diabetes: ongoing challenges, refined procedures, and long-term outcomeSize effect of engineered islets prepared using microfabricated wells on islet cell function and arrangement.Anti-Leukocyte Function-Associated Antigen 1 Therapy in a Nonhuman Primate Renal Transplant Model of Costimulation Blockade-Resistant Rejection.Immunobiology of transplantation: impact on targets for large and small molecules.State of the art of clinical islet transplantation and novel protocols of immunosuppression.Advancing islet transplantation: from engraftment to the immune response.Islet transplantation: factors in short-term islet survival.Generating β cells from stem cells-the story so farTranslating tolerogenic therapies to the clinic - where do we stand?Emerging immune therapies in type 1 diabetes and pancreatic islet transplantation.Targeting co-stimulatory pathways: transplantation and autoimmunity.Tolerance--is it worth it?Regulatory T cells as immunotherapy.Islet transplantation for Type 1 diabetes: where are we now?Innate immunity in solid organ transplantation: an update and therapeutic opportunities.Islet cell transplant: Update on current clinical trials.Memory T cells in organ transplantation: progress and challenges.The state of the art of islet transplantation and cell therapy in type 1 diabetes.T Cell Cosignaling Molecules in Transplantation.Impact of Immune-Modulatory Drugs on Regulatory T Cell.Leukotoxin kills rodent WBC by targeting leukocyte function associated antigen 1.LFA-1 antagonism inhibits early infiltration of endogenous memory CD8 T cells into cardiac allografts and donor-reactive T cell priming.Selective Targeting of High-Affinity LFA-1 Does Not Augment Costimulation Blockade in a Nonhuman Primate Renal Transplantation Model.
P2860
Q26769878-A2DBAC8B-0A35-4D22-AE49-589BCE5A8722Q26798362-30B08F6E-8F69-49CC-B72F-1D671CEF2A46Q26823789-DD8BD389-5F03-4542-BFBF-7CC7838ADD99Q26829578-B2B05E21-37B6-4D0C-A7B3-DE2839FFDF63Q33586165-47C5CF97-0E61-4F70-92C9-D779FCE6AB59Q33848529-0C247B61-B4D4-4D01-BBC0-963113B877FEQ34484801-85C0A8C2-6059-463A-AA15-F740B3A2AFE6Q34729072-255DC914-1638-4C13-919D-830A13877E63Q34976218-FA85D816-DF7F-406E-8D56-A0740C38EC8FQ35585966-D3751807-C45D-4BDB-B853-1DFAF37E0985Q35927610-19752AB8-F2DB-4A81-AB9E-39AB10482552Q36065843-8F7DDC5C-3ED5-4332-BC6E-BD18DD492D3AQ36263810-EF535BB8-DDFB-4DA0-909A-78C72666C2CEQ36305532-3A8CDF32-E794-4011-9020-093B7DA03280Q36538911-840CCD8E-CC0B-4291-8A15-7BABF73F20DBQ36590511-94882169-9F1B-46EC-82C0-A5E01BDB01CDQ37042924-D3796690-9E75-442D-BDCB-98BB0CD7974AQ37088225-B0BA55EF-2EDE-4C7D-9785-55D73519EF5DQ37097382-D51E742F-3FDA-491E-A731-09E6A2E6B9AEQ37343737-EA389DD6-0DDE-480A-832B-CC78A2C9BB29Q37895906-64973ABF-708A-4465-8B16-BC02F3010733Q37914760-0E10EAD8-8433-480A-A537-1CAD4B91E09EQ37914776-1F494DD6-8AEF-498E-8942-923F6D456C04Q37943791-59EE0F22-EE6A-48DF-87AD-911BFDDD4F5CQ38016900-8CFDF49B-0A9B-4DB4-85ED-01921A0DB4FAQ38039091-82C45F6B-86B1-414D-8D9C-0E9676B8EC04Q38063547-EC7719A5-C1C8-4823-94C4-99D32DE64363Q38150101-E9C2FE4D-5AB4-43BC-8B06-BD1905A51AFBQ38174023-A7A97F18-F14A-4260-95EA-F7735B2B363FQ38191610-D751D581-474E-4BB6-9963-B5B01D20AFD7Q38278288-B1015336-5035-46B4-8A07-7692726D545DQ38341632-0579E3FE-7751-4A9A-BE5E-8606C56D9081Q38689971-BC9783BF-8010-4DC2-8C07-F864761CF325Q38753494-0B5039A7-7ABF-4A26-A6E5-DFB21937A241Q38753743-F52ACFDD-74A8-437D-94A0-E7EF888B375DQ38837473-F52D9D5D-FEB9-4CD4-A9B9-7654EF0A14B5Q38918124-1CC95DB8-6700-4153-908E-0346CA356C46Q39065493-19DD0856-EB88-44AE-AF63-862C2F7ABAABQ39101460-2793A4F7-A602-4759-933E-E2EB3A5B780AQ39152748-518BA140-3328-4365-ABB9-52974F581247
P2860
Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Islet transplantation in type ...... nti-LFA-1 antibody efalizumab.
@ast
Islet transplantation in type ...... nti-LFA-1 antibody efalizumab.
@en
Islet transplantation in type ...... nti-LFA-1 antibody efalizumab.
@nl
type
label
Islet transplantation in type ...... nti-LFA-1 antibody efalizumab.
@ast
Islet transplantation in type ...... nti-LFA-1 antibody efalizumab.
@en
Islet transplantation in type ...... nti-LFA-1 antibody efalizumab.
@nl
prefLabel
Islet transplantation in type ...... nti-LFA-1 antibody efalizumab.
@ast
Islet transplantation in type ...... nti-LFA-1 antibody efalizumab.
@en
Islet transplantation in type ...... nti-LFA-1 antibody efalizumab.
@nl
P2093
P2860
P1476
Islet transplantation in type ...... nti-LFA-1 antibody efalizumab.
@en
P2093
A M Posselt
B J Hering
F G Vincenti
J A Bluestone
L A Frassetto
M D Bellin
P2860
P304
P356
10.1111/J.1600-6143.2010.03073.X
P407
P577
2010-08-01T00:00:00Z